The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Intervacc and the Swedish University of Agricultural Sciences, SLU, extends a multi-year contract for the development of innovative animal health vaccines
Stockholm, December 19th, 2022 – Intervacc AB (publ) and the Swedish University of Agricultural Sciences, SLU, announce today that they have extended the contract for the development of animal health vaccines using recombinant proteins. The successful...Strangvac, a vaccine against equine strangles released for sales in Italy
Stockholm, December 13th, 2022 – Intervacc AB (publ) announces today that the first batch of Strangvac®, a vaccine against the highly contagious bacterial equine disease Strangles, has been released for sale in Italy. Dechra Pharmaceuticals PLC distributes the...Strangvac, a vaccine against equine strangles, is now available for sale in Poland
Stockholm, November 28, 2022 – Intervacc AB (publ) announces today that Strangvac® is now available for sale in Poland. Dechra Pharmaceuticals PLC distributes the vaccine in Poland and in a number of other European countries. Poland with its approximately 300 000...Intervacc’s Chief Scientific Officer Dr Andrew Waller participate at the Dutch Equine Conference
Stockholm, November 24, 2022 – The Dutch Equine Conference is one of the Benelux region equine veterinary profession’s events, and it is back again this year! Intervacc’s Chief Scientific Officer Dr Andrew Waller will participate in two sessions about the...Nyhetstjänster
